Home Page

Action required: Please refresh your browser

We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.

More details about this topic are available here »

Companies Map

Companies

Results 1 - 1 out of 1 displayed.

Search filter:

Search for: Company

argenx SE

| | |

Headquarters
Amsterdam, Netherlands

View full record

Main sector:	Biotechnology - Therapeutics and Diagnostics
Subsector:	Anti-infectives Antibodies Immunotherapy
Indications:	Cardiovascular / cardiology Diseases of the blood and blood-forming organs & immune disorders / hematology / immunology Diseases of the eye / ophthalmology Diseases of the nervous system / neurology Endocrine, nutritional and metabolic diseases / endocrinology Genitourinary system / Urology Infectious and parasitic diseases / infectiology / parasitology Musculoskeletal system and connective tissue / Orthopedics Neoplasms / cancer / oncology Respiratory / pulmonology Skin and subcutaneous tissue / dermatology Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified
Employees:	Worldwide: 1,148
Products:	In development: 32 On the market: 8

Description:
argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. The company's product VYVGART is a neonatal Fc receptor blocker indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive. The company's another product VYVGART HYTRULO is a combination of efgartigimod alfa, a neonatal Fc receptor blocker, and hyaluronidase, an endoglycosidase, indicated...

Already have a valid Biotechgate account? Login here »

Get access to Biotechgate

Download complete company profiles including product pipelines, financing rounds and management details.

to the top ↑